ORIGINAL RESEARCH article
Front. Antibiot.
Sec. Antibiotics in Clinical Settings
Volume 4 - 2025 | doi: 10.3389/frabi.2025.1599939
This article is part of the Research TopicEmerging Trends in Phage Therapeutics to Overcome Antibiotic ResistanceView all 3 articles
Demonstration of phage inhibitory action against C. perfringens LMG 11264 within a complex chicken cecal microbiota in vitro
Provisionally accepted- 1TNO, Microbiology and Systems Biology, Leiden, the Netherlands, Defence, Safety and Security, Netherlands Organisation for Applied Scientific Research (TNO), Rijswijk, Netherlands
- 2BaseClear B.V., Leiden, Netherlands
- 3TNO, Microbiology and Systems Biology, Leiden, the Netherlands, Netherlands Organisation for Applied Scientific Research, Amsterdam, North Holland, Netherlands
- 4Netherlands Organisation for Applied Scientific Research, Amsterdam, North Holland, Netherlands
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Clostridium perfringens strains may cause foodborne illness, and 95 % of human infections are linked to the consumption of contaminated meat, including chicken products. In poultry, C. perfringens infection may cause necrotic enteritis, and infections are associated with high mortality rates partially due to antibiotic resistance, which hampers efficient treatment. In vitro screening approaches of alternative treatment options, for instance, specific phages, represent a promising strategy for the selection of novel interventions to combat infections.In this study, we explored the application of a C. perfringens strain LMG 11264 specific phage #7 introduced at 10 4 PFU/mL to inhibit the growth of C. perfringens at 10 6 CFU/ml compared to two antibiotics (amoxicillin 10 µg/ml and clindamycin at 10 µg/ml) within complex chicken cecal microbiota in vitro. Samples for gDNA isolation, qPCR, and metagenome sequencing were taken at the beginning and after 24 and 48 hours of incubation.The C. perfringens LMG 11264 proliferated within the untreated complex microbiota and reached levels of about 10 8 and 10 9 genome equivalents per mL after 24 and 48 hours of incubation, respectively. The phage intervention with phage #7 inhibited the growth of C. perfringens LMG 11264 significantly; the inhibitory effects were similar to those exerted by the antibiotic intervention with amoxicillin and stronger than the inhibitory effects with clindamycin. In the absence of the C. perfringens challenge, we have found a significant effect of ampicillin (p=0.040) or clindamycin (p=0.000017) compared to the untreated control after 24 hours of incubation, the phage addition did not affect the alpha diversity expressed as chao index significantly (p=1). In addition, the endogenous C. perfringens in the chicken microbiota appeared insensitive to phage #7. The phage titer of phage #7 only increased in the presence of the inoculated C. perfringens strain LMG 11264. In conclusion, the i-screen model can be implemented to test the efficacy and specificity of phage therapy in vitro.
Keywords: Phage, Clostridium perfringens, antibiotic resistance, chicken cecal microbiota, in vitro
Received: 25 Mar 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Wiese, Klaassens, Hatt, Kreikamp, Baak, Heerikhuisen and Van Der Vossen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Maria Wiese, TNO, Microbiology and Systems Biology, Leiden, the Netherlands, Defence, Safety and Security, Netherlands Organisation for Applied Scientific Research (TNO), Rijswijk, Netherlands
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.